Suzhou Osaweike Biopharmaceutical Technology

Osaweike Biopharma is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics for autoimmune and inflammatory diseases. The company focuses on high-value kinase targets, including IRAK4 and JAK/TYK2 pathways, to address significant unmet medical needs in dermatology and rheumatology. Their lead programs are currently progressing through early-stage clinical trials, aiming to provide more effective and safer oral treatment options for chronic inflammatory conditions. Osaweike leverages its internal R&D capabilities to advance a pipeline of selective inhibitors with optimized pharmacological profiles.